Table 1.
Main characteristics of the eligible publications.
| First author | Country | Age | Stage | Antibody | Sources of antibody | Staining | Cutoff values (IHC) | Cancer | Clinical features | Survival-MA |
|---|---|---|---|---|---|---|---|---|---|---|
| Total (E+ %) | ||||||||||
| Ong et al. [42] | Singapore | NA | 1–4 | Anti-SOX2 | Clone 57CT23.3.4; Abcam, Cambridge, MA | Cytoplasm | 10% | 310 (NA) | No | CSS |
| Neumann et al. [41] | Germany | 66.5 | NA | Anti-SOX2 | Clone D6D9, cell Signaling technology, Danvers, MA | Nuclei | 10% | 114 (21.1%) | Yes | NA |
| Han et al. [40] | China | NA | NA | Anti-SOX2 | Epitomics | NA | NA | 44 (20.5%) | Yes | NA |
| Lee et al. [39] | Korea | NA | 1–4 | Anti-SOX2 | Abcam, Cambridge, UK | Nuclei | 5% | 110 (17.3%) | Yes | NA |
| Liu et al. [43] | China | NA | 1–4 | Anti-SOX2 | Cell Signaling Technology, Inc | Nuclei | ≥2 scores | 67 (22.4%) | Yes | NA |
| Ma et al. [38] | China | 65 | 1–4 | Anti-SOX2 | ab75485, Abcam, Cambridge, MA | NA | >1.40 | 89 (50.6%) | Yes | NA |
| Raghoebir et al. [37] | The Netherlands | NA | NA | Anti-SOX2 | Immune systems | Nuclei | 5% | 135 (20.7%) | Yes | NA |
| Lundberg et al. [23] | Sweden | NA | 1–4 | Anti-SOX2 | Abcam, Cambridge, UK | Nuclei | NA | 441 (10.7%) | Yes | CSS |
| Yan et al. [36] | China | 65 | 3–4 | Anti-SOX2 | Abcam | NA | 2.5 | 280 (41.8%) | Yes | NA |
| Miller et al. [24] | Australia | 66.7 | 3 | Anti-SOX2 | EPR3131; Abcam cell Signaling Technology, Danvers | Nuclei | NA | 104 (18.3%) | Yes | CSS, OS |
| Zheng et al. [35] | China | NA | 1–4 | Anti-SOX2 | Mass cat. no. 636675, EMD Millipore | NA | NA | 47 (80.9%) | Yes | NA |
| Han et al. [44] | Korea | 59.8 | 3 | Anti-SOX2 | Billerica, MA, USA | NA | ≥1 score | 164 (82.3%) | No | DFS |
| Li et al. [34] | China | NA | 1–4 | Anti-SOX2 | #ab92494 | NA | NA | 432 (NA) | No | OS |
NA: not applicable; IHC: immunohistochemistry; E+: positive/high expression; MA: multivariate Cox analysis; DFS: disease-free survival; OS: overall survival; CSS: cancer-specific survival.